MetaADEDB 2.0 @ LMMD
Cosyntropin
(ZOEFCCMDUURGSE-CQVUSSRSSA-N)
Structure
SMILES
NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)Cc1ccc(cc1)O)C(C)C)CCCCN)C(C)C)CCCNC(=N)N)CCCNC(=N)N)CCCCN)CCCCN)C(C)C)NC(=O)CNC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C(CO)N)Cc1ccc(cc1)O)CO)CCSC)CCC(=O)O)Cc1cnc[nH]1)Cc1ccccc1)CCCNC(=N)N
Molecular Formula:
C136H210N40O31S
Molecular Weight:
2933.440
Log P:
6.7415
Hydrogen Bond Acceptor:
70
Hydrogen Bond Donor:
42
TPSA:
1184.02
CAS Number(s):
16960-16-0
Synonym(s)
1.
Cosyntropin
2.
ACTH (1-24)
3.
Tetracosactide
4.
Tetracosactrin
5.
1-24-ACTH
6.
1-24-Corticotropin
7.
ACTH 1-24
8.
Corticotropin (1-24)-Peptide
9.
Corticotropin (1-24)-Tetracosapeptide
10.
Cortosyn
11.
Cortrosyn
12.
Synthetic ACTH
13.
Tetracosapeptide
14.
ACTH, Synthetic
External Link(s)
MeSHC006418
D003366
PubChem Compound73952237
16129674
16129617
KEGGdr:D00284
Therapeutic Target DatabaseD0W6LI
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Feeling abnormalFAERS: 2US FAERS
2Medication ErrorFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
3AstheniaFAERS: 1US FAERS
4Chest PainFAERS: 1US FAERS
5DizzinessFAERS: 1US FAERS
6DysarthriaFAERS: 1US FAERS
7Foreign body traumaFAERS: 1US FAERS
8HeadacheFAERS: 1US FAERS
9Intercepted medication errorFAERS: 1US FAERS
10MalaiseFAERS: 1US FAERS
11NauseaFAERS: 1US FAERS
12PalpitationsFAERS: 1US FAERS
13ParanoiaFAERS: 1US FAERS
14Pharmaceutical product complaintFAERS: 1US FAERS
15Pharyngolaryngeal PainFAERS: 1US FAERS
16Procedural complicationFAERS: 1US FAERS
17SomnolenceFAERS: 1US FAERS
18StressFAERS: 1US FAERS
19TachycardiaFAERS: 1US FAERS
20TremorFAERS: 1US FAERS
21UrticariaFAERS: 1US FAERS
22treatment failureFAERS: 1US FAERS
23Blood glucose increasedCanada Vigilance: 1Canada Vigilance
24Depressed moodCanada Vigilance: 1Canada Vigilance
25Drug ineffectiveCanada Vigilance: 1Canada Vigilance
26ErythemaCanada Vigilance: 1Canada Vigilance
27Injection site inflammationCanada Vigilance: 1Canada Vigilance
28Injection site painCanada Vigilance: 1Canada Vigilance
29PainCanada Vigilance: 1Canada Vigilance
30Product complaintCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.